Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy NeoGenomics stock in Canada

Own NeoGenomics shares in just a few minutes.

NeoGenomics, Inc (NEO) is a leading diagnostics & research business based in the US. It opened the day at $47.11 after a previous close of $45.93. During the day the price has varied from a low of $46.89 to a high of $48.46. The latest price was $47.9472 (25 minute delay). NeoGenomics is listed on the NASDAQ and employs 1,700 staff. All prices are listed in US Dollars.

How to buy shares in NeoGenomics

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: NEO in this case.
  5. Research NeoGenomics shares. The platform should provide the latest information available.
  6. Buy your NeoGenomics shares. It's that simple.

NeoGenomics share price

Use our graph to track the performance of NEO stocks over time.

NeoGenomics shares at a glance

Information last updated 2021-03-11.
Open$47.11
High$48.46
Low$46.89
Close$47.9472
Previous close$45.93
Change $2.0172
Change % 4.3919%
Volume 304,870
Information last updated 2021-04-23.
52-week range$25.19 - $61.57
50-day moving average $47.9603
200-day moving average $48.753
Wall St. target price$63.2
PE ratio 1346.8422
Dividend yield N/A (0%)
Earnings per share (TTM) $0.038

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available asset types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Deposit and trade $100 and get a $50 bonus.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
CIBC Investor's Edge
Stocks, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$6.95
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0 (if monthly commissions are greater than or equal to US$10.00)
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95-$9.95
$9.95 + $1 per contract
$0
Free
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Investor
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Investor offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
Scotia iTRADE
Options, Mutual Funds, ETFs, GICs, International Equities
$4.99-$9.99
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$0
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy NeoGenomics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

NeoGenomics price performance over time

Historical closes compared with the last close of $47.9472

1 week (2021-04-30) -2.13%
1 month (2021-04-08) 0.16%
3 months (2021-02-08) -14.44%
6 months (2020-11-06) 17.92%
1 year (2020-05-08) 70.63%
2 years (2019-05-08) 115.49%
3 years (2018-05-08) 344.78%
5 years (2016-05-06) 491.21%

Is NeoGenomics under- or over-valued?

Valuing NeoGenomics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NeoGenomics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

NeoGenomics's P/E ratio

NeoGenomics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1347x. In other words, NeoGenomics shares trade at around 1347x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

NeoGenomics's PEG ratio

NeoGenomics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.02. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into NeoGenomics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

NeoGenomics's EBITDA

NeoGenomics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$23.8 million.

The EBITDA is a measure of a NeoGenomics's overall financial performance and is widely used to measure a its profitability.

NeoGenomics financials

Revenue TTM USD$444.4 million
Gross profit TTM USD$186.4 million
Return on assets TTM -0.88%
Return on equity TTM 0.69%
Profit margin 0.94%
Book value $6.195
Market capitalisation USD$6.2 billion

TTM: trailing 12 months

How to short and sell NeoGenomics shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "NEO.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 6.4 million NeoGenomics shares held short by investors – that's known as NeoGenomics's "short interest". This figure is 11.9% up from 5.7 million last month.

There are a few different ways that this level of interest in shorting NeoGenomics shares can be evaluated.

NeoGenomics's "short interest ratio" (SIR)

NeoGenomics's "short interest ratio" (SIR) is the quantity of NeoGenomics shares currently shorted divided by the average quantity of NeoGenomics shares traded daily (recently around 1.1 million). NeoGenomics's SIR currently stands at 5.64. In other words for every 100,000 NeoGenomics shares traded daily on the market, roughly 5640 shares are currently held short.

However NeoGenomics's short interest can also be evaluated against the total number of NeoGenomics shares, or, against the total number of tradable NeoGenomics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NeoGenomics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 NeoGenomics shares in existence, roughly 50 shares are currently held short) or 0.0743% of the tradable shares (for every 100,000 tradable NeoGenomics shares, roughly 74 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against NeoGenomics.

Find out more about how you can short NeoGenomics stock.

NeoGenomics share dividends

We're not expecting NeoGenomics to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

Have NeoGenomics's shares ever split?

NeoGenomics's shares were split on a 1:100 basis on 15 April 2003. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NeoGenomics shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for NeoGenomics shares which in turn could have impacted NeoGenomics's share price.

NeoGenomics share price volatility

Over the last 12 months, NeoGenomics's shares have ranged in value from as little as $25.19 up to $61.57. A popular way to gauge a stock's volatility is its "beta".

NEO.US volatility(beta: 0.68)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NeoGenomics's is 0.6845. This would suggest that NeoGenomics's shares are less volatile than average (for this exchange).

NeoGenomics overview

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited; and has collaboration with Elevation Oncology to expand genomic testing for NRG1 fusions across solid tumors. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site